JP Morgan Chase’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

JP Morgan Chase’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-300,000	Closed	-$36K	–	7859
2024 Q4	$36K	Hold	300,000	–	–	﹤0.01%	6117
2024 Q3	$31.3K	Hold	300,000	–	–	﹤0.01%	6129
2024 Q2	$33.3K	Hold	300,000	–	–	﹤0.01%	6002
2024 Q1	$45K	Hold	300,000	–	–	﹤0.01%	5991
2023 Q4	$45K	Buy	+300,000	New	+$48.5K	﹤0.01%	6027

JP Morgan Chase's BLACR Position: Q1 2025 in Review

JP Morgan Chase sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 300,000 shares — an estimated $36K sold.

JP Morgan Chase first reported a position in BLACR in Q4 2023 and held it in 5 quarters. The position peaked at $45K in Q1 2024. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

JP Morgan Chase reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
JP Morgan Chase sold 300,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $36K.
JP Morgan Chase first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q4 2023 and held it in 5 quarters.
JP Morgan Chase's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $45K in Q1 2024.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.